Chronic kidney disease in children and the role of epigenetics: Future therapeutic trajectories (Review)

Uwaezuoke,Samuel   N.; Okafor,Henrietta   U.; Muoneke,Vivian   N.; Odetunde,Odutola   I.; Odimegwu,Chioma   L.

doi:10.3892/br.2016.781

Chronic kidney disease in children and the role of epigenetics: Future therapeutic trajectories (Review)

Authors:
- Samuel N. Uwaezuoke
- Henrietta U. Okafor
- Vivian N. Muoneke
- Odutola I. Odetunde
- Chioma L. Odimegwu
View Affiliations

Affiliations: Department of Pediatrics, College of Medicine, University of Nigeria Teaching Hospital, Ituku‑Ozalla, Enugu 400001, Nigeria, Department of Pediatrics, University of Nigeria Teaching Hospital, Ituku‑Ozalla, Enugu 400001, Nigeria
Published online on: October 18, 2016 https://doi.org/10.3892/br.2016.781
Pages: 660-664

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Global differences in the observed causes of chronic kidney disease (CKD) in children are well documented and are attributed to dissimilarities in clime, race, hereditary, and ancestry. Thus, familial clustering and disparities in CKD prevalence rates across ethnic and racial groups indicate that the progression of renal disease has a strong genetic component. Mammalian studies have demonstrated a feasible nexus between nutrition and non‑genetic exposure (around the time of conception and in epigenetic changes) in the expression of major genes identified in renal organogenesis. The major consequence is a reduction in the number of nephrons, with subsequent predisposition to hypertension and CKD. Identifying these epigenetic changes is crucial (due to their potentially reversible nature), as they may serve as future therapeutic targets to prevent kidney fibrosis and CKD. Despite progress in the field of epigenetics in oncology, research in other subspecialties of medicine is largely experimental with few existing studies regarding the clinical implication of epigenetics in renal disease. Therapeutic trajectories for CKD in children based on the influence of epigenetics may eventually revolutionize the management of this disease. The aim of the current narrative review is to appraise the role of epigenetics in CKD, and highlight the potential future therapeutic pathways.

View Figures

View References

1	World Kidney Day, . Chronic Kidney Disease. 2015.http://www.worldkidneyday.org/faqs/chronic-kidney-disease/Accessed October 10, 2014.
2	Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY and Yang CW: Chronic kidney disease: Global dimension and perspectives. Lancet. 382:260–272. 2013. View Article : Google Scholar : PubMed/NCBI
3	Couser WG, Remuzzi G, Mendis S and Tonelli M: The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 80:1258–1270. 2011. View Article : Google Scholar : PubMed/NCBI
4	Harambat J, van Stralen KJ, Kim JJ and Tizard EJ: Epidemiology of chronic kidney disease in children. Pediatr Nephrol. 27:363–373. 2012. View Article : Google Scholar : PubMed/NCBI
5	Warady BA and Chadha V: Chronic kidney disease in children: The global perspective. Pediatr Nephrol. 22:1999–2009. 2007. View Article : Google Scholar : PubMed/NCBI
6	Bowden DW: Genetics of kidney disease. Kidney Int Suppl. 83:S8–S12. 2003. View Article : Google Scholar
7	Lei HH, Perneger TV, Klag MJ, Whelton PK and Coresh J: Familial aggregation of renal disease in a population-based case-control study. J Am Soc Nephrol. 9:1270–1276. 1998.PubMed/NCBI
8	Hsu CY, Lin F, Vittinghoff E and Shlipak MG: Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 14:2902–2907. 2003. View Article : Google Scholar : PubMed/NCBI
9	Freedman BI, Spray BJ, Tuttle AB and Buckalew VM Jr: The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis. 21:387–393. 1993. View Article : Google Scholar : PubMed/NCBI
10	Köttgen A, Pattaro C, Böger CA, Fuchsberger C, Olden M, Glazer NL, Parsa A, Gao X, Yang Q, Smith AV, et al: New loci associated with kidney function and chronic kidney disease. Nat Genet. 42:376–384. 2010. View Article : Google Scholar : PubMed/NCBI
11	Liakopoulos V, Georgianos PI, Eleftheriadis T and Sarafidis PA: Epigenetic mechanisms and kidney diseases. Curr Med Chem. 18:1733–1739. 2011. View Article : Google Scholar : PubMed/NCBI
12	Dwivedi RS, Herman JG, McCaffrey TA and Raj DSC: Beyond genetics: Epigenetic code in chronic kidney disease. Kidney Int. 79:23–32. 2011. View Article : Google Scholar : PubMed/NCBI
13	Slack JM: Conrad Hal Waddington: The last Renaissance biologist? Nat Rev Genet. 3:889–895. 2002. View Article : Google Scholar : PubMed/NCBI
14	Nanney DL: Epigenetic control systems. Proc Natl Acad Sci USA. 44:712–717. 1958. View Article : Google Scholar : PubMed/NCBI
15	Riggs A, Martienssen R and Russo V: Epigenetic mechanisms of gene regulation. 32. Cold Spring Harbor Laboratory Press; 1996
16	Bird A: Perceptions of epigenetics. Nature. 447:396–398. 2007. View Article : Google Scholar : PubMed/NCBI
17	Berger SL, Kouzarides T, Shiekhattar R and Shilatifard A: An operational definition of epigenetics. Genes Dev. 23:781–783. 2009. View Article : Google Scholar : PubMed/NCBI
18	Bonasio R, Tu S and Reinberg D: Molecular signals of epigenetic states. Science. 330:612–616. 2010. View Article : Google Scholar : PubMed/NCBI
19	Link A, Balaguer F and Goel A: Cancer chemoprevention by dietary polyphenols: Promising role for epigenetics. Biochem Pharmacol. 80:1771–1792. 2010. View Article : Google Scholar : PubMed/NCBI
20	Sadikovic B, Al-Romaih K, Squire JA and Zielenska M: Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics. 9:394–408. 2008. View Article : Google Scholar : PubMed/NCBI
21	Luch A: Nature and nurture-lessons from chemical carcinogenesis. Nat Rev Cancer. 5:113–125. 2005. View Article : Google Scholar : PubMed/NCBI
22	Perna AF, Ingrosso D, Galletti P, Zappia V and De Santo NG: Membrane protein damage and methylation reactions in chronic renal failure. Kidney Int. 50:358–366. 1996. View Article : Google Scholar : PubMed/NCBI
23	Robertson KD and Wolffe AP: DNA methylation in health and disease. Nat Rev Genet. 1:11–19. 2000. View Article : Google Scholar : PubMed/NCBI
24	Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, Vacca M, D'Esposito M, D'Urso M, Galletti P, et al: Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet. 361:1693–1699. 2003. View Article : Google Scholar : PubMed/NCBI
25	Ptak C and Petronis A: Epigenetics and complex disease: From etiology to new therapeutics. Annu Rev Pharmacol Toxicol. 48:257–276. 2008. View Article : Google Scholar : PubMed/NCBI
26	Huang Y, Chang X, Lee J, Cho YG, Zhong X, Park IS, Liu JW, Califano JA, Ratovitski EA, Sidransky D, et al: Cigarette smoke induces promoter methylation of single-stranded DNA-binding protein 2 in human esophageal squamous cell carcinoma. Int J Cancer. 128:2261–2273. 2011. View Article : Google Scholar : PubMed/NCBI
27	Nakajima K, Takeoka M, Mori M, Hashimoto S, Sakurai A, Nose H, Higuchi K, Itano N, Shiohara M, Oh T, et al: Exercise effects on methylation of ASC gene. Int J Sports Med. 31:671–675. 2010. View Article : Google Scholar : PubMed/NCBI
28	Oommen AM, Griffin JB, Sarath G and Zempleni J: Roles for nutrients in epigenetic events. J Nutr Biochem. 16:74–77. 2005. View Article : Google Scholar : PubMed/NCBI
29	Duthie SJ: Folic acid deficiency and cancer: Mechanisms of DNA instability. Br Med Bull. 55:578–592. 1999. View Article : Google Scholar : PubMed/NCBI
30	Peterson CL and Laniel MA: Histones and histone modifications. Curr Biol. 14:R546–R551. 2004. View Article : Google Scholar : PubMed/NCBI
31	Jenuwein T: Re-SET-ting heterochromatin by histone methyltransferases. Trends Cell Biol. 11:266–273. 2001. View Article : Google Scholar : PubMed/NCBI
32	Tang W, Luo XY and Sanmuels V: Gene silencing: Double-stranded RNA mediated mRNA degradation and gene inactivation. Cell Res. 11:181–186. 2001. View Article : Google Scholar : PubMed/NCBI
33	Wassenegger M: The role of the RNAi machinery in heterochromatin formation. Cell. 122:13–16. 2005. View Article : Google Scholar : PubMed/NCBI
34	Schena FP, Serino G and Sallustio F: MicroRNAs in kidney diseases: New promising biomarkers for diagnosis and monitoring. Nephrol Dial Transplant. 29:755–763. 2014. View Article : Google Scholar : PubMed/NCBI
35	Woroniecki R, Gaikwad AB and Susztak K: Fetal environment, epigenetics, and pediatric renal disease. Pediatr Nephrol. 26:705–711. 2011. View Article : Google Scholar : PubMed/NCBI
36	Zandi-Nejad K, Luyckx VA and Brenner BM: Adult hypertension and kidney disease: The role of fetal programming. Hypertension. 47:502–508. 2006. View Article : Google Scholar : PubMed/NCBI
37	Luyckx VA and Brenner BM: Low birth weight, nephron number, and kidney disease. Kidney Int Suppl. 68:S68–S77. 2005. View Article : Google Scholar
38	Alexander BT: Intrauterine growth restriction and reduced glomerular number: Role of apoptosis. Am J Physiol Regul Integr Comp Physiol. 285:R933–R934. 2003. View Article : Google Scholar : PubMed/NCBI
39	Hughson MD, Douglas-Denton R, Bertram JF and Hoy WE: Hypertension, glomerular number, and birth weight in African Americans and white subjects in the southeastern United States. Kidney Int. 69:671–678. 2006. View Article : Google Scholar : PubMed/NCBI
40	Hodgin JB, Rasoulpour M, Markowitz GS and D'Agati VD: Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 4:71–76. 2009. View Article : Google Scholar : PubMed/NCBI
41	Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller CA, Kalluri R and Zeisberg M: Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 16:544–550. 2010. View Article : Google Scholar : PubMed/NCBI
42	Sayyed SG, Gaikwad AB, Lichtnekert J, Kulkarni O, Eulberg D, Klussmann S, Tikoo K and Anders HJ: Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and β phosphorylation at serine 10. Nephrol Dial Transplant. 25:1811–1817. 2010. View Article : Google Scholar : PubMed/NCBI
43	Gaikwad AB, Sayyed SG, Lichtnekert J, Tikoo K and Anders HJ: Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes. Am J Pathol. 176:1079–1083. 2010. View Article : Google Scholar : PubMed/NCBI
44	Pentz ES, Lopez ML, Kim HS, Carretero O, Smithies O and Gomez RA: Ren1d and Ren2 cooperate to preserve homeostasis: Evidence from mice expressing GFP in place of Ren1d. Physiol Genomics. 6:45–55. 2001.PubMed/NCBI
45	Gomez RA, Pentz ES, Jin X, Cordaillat M and Lopez ML Sequeira: CBP and p300 are essential for renin cell identity and morphological integrity of the kidney. Am J Physiol Heart Circ Physiol. 296:H1255–H1262. 2009. View Article : Google Scholar : PubMed/NCBI
46	Shi S, Yu L, Chiu C, Sun Y, Chen J, Khitrov G, Merkenschlager M, Holzman LB, Zhang W, Mundel P, et al: Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol. 19:2159–2169. 2008. View Article : Google Scholar : PubMed/NCBI
47	Ho JJ and Marsden PA: Dicer cuts the kidney. J Am Soc Nephrol. 19:2043–2046. 2008. View Article : Google Scholar : PubMed/NCBI
48	Harvey SJ, Jarad G, Cunningham J, Goldberg S, Schermer B, Harfe BD, McManus MT, Benzing T and Miner JH: Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol. 19:2150–2158. 2008. View Article : Google Scholar : PubMed/NCBI
49	Ho J, Ng KH, Rosen S, Dostal A, Gregory RI and Kreidberg JA: Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol. 19:2069–2075. 2008. View Article : Google Scholar : PubMed/NCBI
50	Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, Vacca M, D'Esposito M, D'Urso M, Galletti P, et al: Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet. 361:1693–1699. 2003. View Article : Google Scholar : PubMed/NCBI
51	Newman PE: Can reduced folic acid and vitamin B12 levels cause deficient DNA methylation producing mutations which initiate atherosclerosis? Med Hypotheses. 53:421–424. 1999. View Article : Google Scholar : PubMed/NCBI
52	Ptak C and Petronis A: Epigenetics and complex disease: From etiology to new therapeutics. Annu Rev Pharmacol Toxicol. 48:257–276. 2008. View Article : Google Scholar : PubMed/NCBI
53	Griffiths EA and Gore SD: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 45:23–30. 2008. View Article : Google Scholar : PubMed/NCBI
54	Fukuda N: Development of gene therapies for cardiovascular and renal diseases by nucleic acid medicines. Med Chem. 2:13–19. 2006. View Article : Google Scholar : PubMed/NCBI